Wikisage, the free encyclopedia of the second generation, is digital heritage

Fabry disease: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
m (template)
Line 1: Line 1:
Fabry disease is a genetic condition involving lysosomal storage (E75.2)<ref>https://de.wikipedia.org/wiki/Morbus_Fabry</ref>is an X-linked disorder caused by alpha-galactosidase A deficiency
Fabry disease is a genetic condition involving lysosomal storage <ref>https://de.wikipedia.org/wiki/Morbus_Fabry</ref>is an X-linked disorder caused by alpha-galactosidase A deficiency
<ref>https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0877-4
<ref>https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0877-4
</ref>
</ref>
{{disease|Fabry disease|E75.2}}
<gallery>File:Morbus Fabry affected organs.svg.png</gallery>
<gallery>File:Morbus Fabry affected organs.svg.png</gallery>
[[migalastat]] or 1-deoxygalactonojirimycin received an orphan drug approval
[[migalastat]] or 1-deoxygalactonojirimycin received an orphan drug approval

Revision as of 03:18, 11 August 2018

Fabry disease is a genetic condition involving lysosomal storage [1]is an X-linked disorder caused by alpha-galactosidase A deficiency [2]

Disease classification WHO
Fabry disease E75.2

migalastat or 1-deoxygalactonojirimycin received an orphan drug approval [3]

  • improves diarrhea

https://ojrd.biomedcentral.com/articles/10.1186/s13023-018-0813-7 Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY


Anderson-Fabry disease in heart failure

Galafold [summary of product characteristics]. Buckinghamshire, UK; Amicus Therapeutics UK Ltd: 2017